1. Home
  2. Medical Research
  3. New York, NY
  4. Global Alliance for Tb Drug Development

Global Alliance for Tb Drug Development

Global Alliance for Tb Drug Development is ranked #4 of 39 medical research organizations in New York, NY, with an America's Best Score of 87 out of 100, based on its 2025 Form 990.

  • New York, NY
  • Tax-exempt since 2000
  • EIN: 13-4128413
tballiance.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
87OF 100 #4 of 39 in New York ranked medical research organizations How this score is calculated

Organization summary

Global Alliance for Tb Drug Development is a 501(c)(3) organization, classified under Medical Research (NTEE H80). Contributions are tax-deductible.

80 Pine Street 20Th Flr, New York, NY 10005-1755

Among the 61 scored medical research organizations in New York, Global Alliance for Tb Drug Development holds 42.2 months of operating reserves (peer median 13.5 months), runs a typical yearly surplus of 2.2% (peers: surplus of 3.4%), and has cut spending 1.2% a year (peers: grown spending 7.0% a year).

In fiscal year 2025 it reported $52,545,056 in revenue and $53,891,336 in expenses, with contributions making up 79.7% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Tb alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Largest programs · fiscal year 2025

  • Research and development - tb alliance is a not-for-profit product development partnership (pdp), uniquely positioned to leverage a global network of public and private partners to most efficiently advance tb drug development. A pdp builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. Pdps retain dire… Read more

    Research and development - tb alliance is a not-for-profit product development partnership (pdp), uniquely positioned to leverage a global network of public and private partners to most efficiently advance tb drug development. A pdp builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. Pdps retain direct management oversight of their projects, though much of the laboratory and clinical work is done through external research facilities and contractors. We combine the research and development expertise of our staff with the skills and resources of our partners to harness the most promising science wherever it may exist around the world. This model minimizes costs, including overhead and investments in infrastructure, while optimizing scientific capability to speed new tb drug development. Our business model and diverse partnerships allow tb alliance to leverage additional partner services for every dollar invested in its programs. Nc-009 - nc-009 is a pan-phase 2 clinical trial incorporating elements of phase 2a, b, and c to evaluate the safety and efficacy of a combination of a new experimental compound, sorfequiline (formerly known as tbaj-876), with pretomanid and linezolid, components of tb alliance's bpal regimen. This regimen has the potential to shorten and improve treatment for both drug-sensitive and drug-resistant forms of tb. Results from preclinical and phase 1 studies were presented at the 2023 union conference on lung health and showed that the new compound, sorfequiline, when compared with bedaquiline (a tb medicine in the same drug class), eliminated tb bacteria faster and had a potentially safer profile. Nc-009 tested different doses of sorfequiline in combination with pretomanid and linezolid against the current standard of care for drug-sensitive tb - isoniazid, rifampicin, pyrazinamide, and ethembutol (hrze). Another arm of the trial also tested pretomanid and linezolid in combination with bedaquiline (bpal), a regimen now recommended by the world health organization to treat some forms of dr-tb, against drug-sensitive tb. The study enrolled approximately 300 participants with drug-sensitive tb at 21 clinical trial sites in five countries: Georgia, philippines, south africa, tanzania, and uganda. The results of the nc-009 clinical trial were presented at the 2025 union world conference on lung health in copenhagen. The results of the trial showed that, overall, sorfequiline had greater activity than bedaquiline. The 100 mg spal regimen had greater activity against tb than the standard of care hrze (isoniazid, rifampin, pyrazinamide, and ethambutol), indicating the potential to shorten treatment time for active tb. In addition, the spal regimen had a comparable safety profile to the standard of care for people with drug-sensitive tb (ds-tb). Q203 - telacebec (q203) is a first in-class drug candidate against mycobacterium tuberculosis infection. Q203 targets cytochrome bc1 complex and shows potent activity against multidrug-resistant tuberculosis (mdr-tb). Q203 has also been found effective against buruli ulcer (mycobacterium ulcerans), a chronic, necrotizing disease that affects skin and sometimes bone and can lead to permanent deformity and long-term disability, and leprosy (mycobacterium leprae). In 2023, tb alliance in-licensed q203 from qurient, a clinical-stage biotechnology company based in south korea. In July 2024, a phase 2 proof-of-concept study was initiated to explore the use of telacebec (q203) to treat buruli ulcer. If successful, a single drug could cut treatment duration by more than half. In partnership with tb alliance and with support from qurient co. Ltd, professor daniel o'brien - a prominent clinician-researcher and expert in buruli ulcer - is leading the study at barwon health and the royal melbourne hospital in australia. The first cohort for the trial enrolled approximately 40 adult patients with buruli ulcer who will receive 28 days of telacebec (300mg) once daily, followed by a year of observation. Preliminary results were reported in 2025 and were positive. A second cohort of participants, about 80 additional participants, were enrolled by the beginning of 2026 and the trial is currently ongoing. Tbaj-587 - this next-generation diarylquinoline project has shown potential to maintain bedaquiline's impressive anti-tb activities while retaining additional improved properties. Tbaj-587 is being studied through the innovative health initiative's era4tb project and, in 2024, tbaj-587 completed a phase I trial demonstrating positive results. Results publications are underway. As of August 2026, the phase 2 trial, named synergy, will soon begin enrollment in south africa under the innovative health initiative's unite4tb program.

    $40,409,317 spent · 86.2% of program spending
  • Public affairs and policy - tb alliance maintains critical alliances with public and private organizations to raise awareness about tuberculosis ("tb") and advocate for public and private involvement in research for the public good. Specifically, tb alliance negotiates terms that support the development and access of new affordable anti-tb drugs equitably for those areas most in need while encoura… Read more

    Public affairs and policy - tb alliance maintains critical alliances with public and private organizations to raise awareness about tuberculosis ("tb") and advocate for public and private involvement in research for the public good. Specifically, tb alliance negotiates terms that support the development and access of new affordable anti-tb drugs equitably for those areas most in need while encouraging the private sector on the development of these medicines. Tb alliance continues to pursue an explicit commitment to our "aaa mandate" - that all new products will be adopted, available and affordable to those with tb.

    $5,645,557 spent · 12.0% of program spending
  • Business development - tb alliance negotiates, implements and manages agreements with public and private organizations worldwide and does so by adhering to sound business practices while ensuring the public good. Specifically, tb alliance negotiates terms that support the development and access of new affordable anti-tb drugs equitably to those areas most in need while encouraging the private sect… Read more

    Business development - tb alliance negotiates, implements and manages agreements with public and private organizations worldwide and does so by adhering to sound business practices while ensuring the public good. Specifically, tb alliance negotiates terms that support the development and access of new affordable anti-tb drugs equitably to those areas most in need while encouraging the private sector to help develop new medicines for tb indications.

    $811,284 spent · 1.7% of program spending

Where each dollar went · fiscal year 2025

Of every dollar it spent, 87¢ went to programs, 11¢ to management and 2¢ to fundraising.

  • Programs $46,866,158
  • Management $5,910,799
  • Fundraising $1,114,379

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score87 / 100
Rank in New York#4 of 39
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves42.2 mo; 4.6 mo in cash25 / 25
Financial balance (median margin)+2.2%15.6 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth−1.2% / yr6.9 / 15
Track record26 years10 / 10
Debt load13.5% of assets9.3 / 10
Total86.9 → 87
Spending on programs
Not scored; America's Best needs 65%+
87%Meets

Compared with New York peers

MeasureThis organizationPeer median
Operating reserves42.2 mo13.5 mo
Typical margin+2.2%+3.4%
Spending growth−1.2% / yr+7.0% / yr
Debt load13.5%13.5%

Peers: the 61 New York medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$52,545,056Fiscal year 20252022: $56,212,96320222023: $60,240,48620232024: $63,732,55720242025: $52,545,0562025
Expenses$53,891,336Fiscal year 20252022: $55,785,89020222023: $55,378,57920232024: $61,508,78320242025: $53,891,3362025
Total assets$219,365,830Fiscal year 20252022: $176,686,87920222023: $197,319,54120232024: $204,316,42820242025: $219,365,8302025
Total liabilities$29,669,070Fiscal year 20252022: $11,506,36020222023: $25,619,99120232024: $28,006,59920242025: $29,669,0702025
Fiscal year ending December 2025
Revenue$52,545,056
Expenses$53,891,336
Net income−$1,346,280
Net assets$189,696,760

Notable sources of revenue

Percent of total revenue
Contributions$41,898,401
Program services$0
Investment income$7,946,317
Other (net)$2,700,338

Assets / debt

Total assets$219,365,830
Total liabilities$29,669,070
Net assets$189,696,760

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$63,732,557
Expenses$61,508,783
Net income$2,223,774
Net assets$176,309,829

Notable sources of revenue

Percent of total revenue
Contributions$52,737,212
Program services$0
Investment income$9,675,203
Other (net)$1,320,142

Assets / debt

Total assets$204,316,428
Total liabilities$28,006,599
Net assets$176,309,829

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$60,240,486
Expenses$55,378,579
Net income$4,861,907
Net assets$171,699,550

Notable sources of revenue

Percent of total revenue
Contributions$49,796,816
Program services$0
Investment income$8,182,816
Other (net)$2,260,854

Assets / debt

Total assets$197,319,541
Total liabilities$25,619,991
Net assets$171,699,550

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$56,212,963
Expenses$55,785,890
Net income$427,073
Net assets$165,180,519

Notable sources of revenue

Percent of total revenue
Contributions$52,646,326
Program services$0
Investment income$2,653,344
Other (net)$913,293

Assets / debt

Total assets$176,686,879
Total liabilities$11,506,360
Net assets$165,180,519

Compensation

Officers and key employees$3,962,233
Share of expenses7.1%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?